Skip to main content
TV Ad Spend Leaderboard

Who spends the most on TV drug ads?

Prescription medications ranked by TVPills internal editorial estimates of annual TV ad budgets. These are not measured year-to-date or realized full-year spending.

Share

Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)

Estimated Annual Budget Total

$13.2B

Drugs Ranked

145

  1. 1

    Humira

    US

    adalimumab · Rheumatoid arthritis, psoriasis, Crohn's disease

    Unverified catalogue summary (leaderboard identity and indication) for Humira in US; not checked against current local product information.

    $500M

    editorial est. / yr · catalogue record

  2. 2

    Skyrizi

    US

    risankizumab-rzaa · Plaque psoriasis, psoriatic arthritis, Crohn's disease

    Unverified catalogue summary (leaderboard identity and indication) for Skyrizi in US; not checked against current local product information.

    $480M

    editorial est. / yr · catalogue record

  3. 3

    Ozempic

    US

    semaglutide · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Ozempic in US; not checked against current local product information.

    $420M

    editorial est. / yr · catalogue record

  4. 4

    Dupixent

    US

    dupilumab · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Dupixent in US; not checked against current local product information.

    $390M

    editorial est. / yr · catalogue record

  5. 5

    Wegovy

    US

    semaglutide · Chronic weight management, cardiovascular risk reduction

    Unverified catalogue summary (leaderboard identity and indication) for Wegovy in US; not checked against current local product information.

    $380M

    editorial est. / yr · catalogue record

  6. 6

    Eliquis

    US

    apixaban · Blood clots, nonvalvular atrial fibrillation

    Unverified catalogue summary (leaderboard identity and indication) for Eliquis in US; not checked against current local product information.

    $350M

    editorial est. / yr · catalogue record

  7. 7

    Mounjaro

    US

    tirzepatide · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Mounjaro in US; not checked against current local product information.

    $350M

    editorial est. / yr · catalogue record

  8. 8

    Zepbound

    US

    tirzepatide · Chronic weight management, obstructive sleep apnea

    Unverified catalogue summary (leaderboard identity and indication) for Zepbound in US; not checked against current local product information.

    $300M

    editorial est. / yr · catalogue record

  9. 9

    Jardiance

    US

    empagliflozin · Type 2 diabetes, heart failure, chronic kidney disease

    Unverified catalogue summary (leaderboard identity and indication) for Jardiance in US; not checked against current local product information.

    $280M

    editorial est. / yr · catalogue record

  10. 10

    Keytruda

    US

    pembrolizumab · Multiple cancers

    Unverified catalogue summary (leaderboard identity and indication) for Keytruda in US; not checked against current local product information.

    $260M

    editorial est. / yr · catalogue record

  11. 11

    Trulicity

    US

    dulaglutide · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Trulicity in US; not checked against current local product information.

    $240M

    editorial est. / yr · catalogue record

  12. 12

    Farxiga

    US

    dapagliflozin · Type 2 diabetes, heart failure, chronic kidney disease

    Unverified catalogue summary (leaderboard identity and indication) for Farxiga in US; not checked against current local product information.

    $220M

    editorial est. / yr · catalogue record

  13. 13

    Xarelto

    US

    rivaroxaban · Blood clots, nonvalvular atrial fibrillation

    Unverified catalogue summary (leaderboard identity and indication) for Xarelto in US; not checked against current local product information.

    $210M

    editorial est. / yr · catalogue record

  14. 14

    Vraylar

    US

    cariprazine · Schizophrenia (age 13+), bipolar I mania/mixed episodes (age 10+), adult bipolar I depression, adult MDD (add-on)

    Unverified catalogue summary (leaderboard identity and indication) for Vraylar in US; not checked against current local product information.

    $200M

    editorial est. / yr · catalogue record

  15. 15

    Trelegy Ellipta

    US

    fluticasone furoate/umeclidinium/vilanterol · COPD, asthma

    Unverified catalogue summary (leaderboard identity and indication) for Trelegy Ellipta in US; not checked against current local product information.

    $200M

    editorial est. / yr · catalogue record

  16. 16

    Taltz

    US

    ixekizumab · Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis

    Unverified catalogue summary (leaderboard identity and indication) for Taltz in US; not checked against current local product information.

    $190M

    editorial est. / yr · catalogue record

  17. 17

    Nurtec ODT

    US

    rimegepant · Adult migraine: acute treatment and episodic prevention

    Unverified catalogue summary (leaderboard identity and indication) for Nurtec ODT in US; not checked against current local product information.

    $190M

    editorial est. / yr · catalogue record

  18. 18

    Rybelsus

    US

    semaglutide · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Rybelsus in US; not checked against current local product information.

    $180M

    editorial est. / yr · catalogue record

  19. 19

    Biktarvy

    US

    bictegravir/emtricitabine/tenofovir alafenamide · HIV-1 infection

    Unverified catalogue summary (leaderboard identity and indication) for Biktarvy in US; not checked against current local product information.

    $180M

    editorial est. / yr · catalogue record

  20. 20

    Rinvoq

    US

    upadacitinib · Rheumatoid arthritis, psoriatic arthritis, eczema

    Unverified catalogue summary (leaderboard identity and indication) for Rinvoq in US; not checked against current local product information.

    $175M

    editorial est. / yr · catalogue record

  21. 21

    Rexulti

    US

    brexpiprazole · Adult major depression (add-on), schizophrenia (age 13+), agitation associated with dementia due to Alzheimer's disease

    Unverified catalogue summary (leaderboard identity and indication) for Rexulti in US; not checked against current local product information.

    $170M

    editorial est. / yr · catalogue record

  22. 22

    Cosentyx

    US

    secukinumab · Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis

    Unverified catalogue summary (leaderboard identity and indication) for Cosentyx in US; not checked against current local product information.

    $160M

    editorial est. / yr · catalogue record

  23. 23

    Ubrelvy

    US

    ubrogepant · Acute migraine

    Unverified catalogue summary (leaderboard identity and indication) for Ubrelvy in US; not checked against current local product information.

    $160M

    editorial est. / yr · catalogue record

  24. 24

    Entresto

    US

    sacubitril/valsartan · Chronic heart failure

    Unverified catalogue summary (leaderboard identity and indication) for Entresto in US; not checked against current local product information.

    $150M

    editorial est. / yr · catalogue record

  25. 25

    Opdivo

    US

    nivolumab · Multiple cancers

    Unverified catalogue summary (leaderboard identity and indication) for Opdivo in US; not checked against current local product information.

    $150M

    editorial est. / yr · catalogue record

  26. 26

    Austedo

    US

    deutetrabenazine · Tardive dyskinesia, Huntington's chorea

    Unverified catalogue summary (leaderboard identity and indication) for Austedo in US; not checked against current local product information.

    $150M

    editorial est. / yr · catalogue record

  27. 27

    Xiidra

    US

    lifitegrast · Dry eye disease

    Unverified catalogue summary (leaderboard identity and indication) for Xiidra in US; not checked against current local product information.

    $150M

    editorial est. / yr · catalogue record

  28. 28

    Shingrix

    US

    zoster vaccine recombinant, adjuvanted · Shingles prevention

    Unverified catalogue summary (leaderboard identity and indication) for Shingrix in US; not checked against current local product information.

    $150M

    editorial est. / yr · catalogue record

  29. 29

    Tremfya

    US

    guselkumab · Plaque psoriasis, psoriatic arthritis

    Unverified catalogue summary (leaderboard identity and indication) for Tremfya in US; not checked against current local product information.

    $140M

    editorial est. / yr · catalogue record

  30. 30

    Linzess

    US

    linaclotide · IBS with constipation (age 7+), adult chronic idiopathic constipation, pediatric functional constipation (age 2+)

    Unverified catalogue summary (leaderboard identity and indication) for Linzess in US; not checked against current local product information.

    $140M

    editorial est. / yr · catalogue record

  31. 31

    Myrbetriq

    US

    mirabegron · Overactive bladder

    Unverified catalogue summary (leaderboard identity and indication) for Myrbetriq in US; not checked against current local product information.

    $140M

    editorial est. / yr · catalogue record

  32. 32

    Stelara

    US

    ustekinumab · Psoriasis, Crohn's disease, ulcerative colitis

    Unverified catalogue summary (leaderboard identity and indication) for Stelara in US; not checked against current local product information.

    $130M

    editorial est. / yr · catalogue record

  33. 33

    Caplyta

    US

    lumateperone · Adult schizophrenia, bipolar I/II depression, major depression (add-on)

    Unverified catalogue summary (leaderboard identity and indication) for Caplyta in US; not checked against current local product information.

    $130M

    editorial est. / yr · catalogue record

  34. 34

    Trintellix

    US

    vortioxetine · Major depressive disorder

    Unverified catalogue summary (leaderboard identity and indication) for Trintellix in US; not checked against current local product information.

    $130M

    editorial est. / yr · catalogue record

  35. 35

    Xifaxan

    US

    rifaximin · Irritable bowel syndrome with diarrhea, hepatic encephalopathy

    Unverified catalogue summary (leaderboard identity and indication) for Xifaxan in US; not checked against current local product information.

    $130M

    editorial est. / yr · catalogue record

  36. 36

    Sotyktu

    US

    deucravacitinib · Adult moderate-to-severe plaque psoriasis; adult active psoriatic arthritis

    Unverified catalogue summary (leaderboard identity and indication) for Sotyktu in US; not checked against current local product information.

    $130M

    editorial est. / yr · catalogue record

  37. 37

    Repatha

    US

    evolocumab · High cholesterol, cardiovascular disease

    Unverified catalogue summary (leaderboard identity and indication) for Repatha in US; not checked against current local product information.

    $120M

    editorial est. / yr · catalogue record

  38. 38

    Qulipta

    US

    atogepant · Migraine prevention

    Unverified catalogue summary (leaderboard identity and indication) for Qulipta in US; not checked against current local product information.

    $120M

    editorial est. / yr · catalogue record

  39. 39

    Breztri Aerosphere

    US

    budesonide/glycopyrrolate/formoterol · Maintenance COPD in adults; maintenance asthma (age 12+)

    Unverified catalogue summary (leaderboard identity and indication) for Breztri Aerosphere in US; not checked against current local product information.

    $120M

    editorial est. / yr · catalogue record

  40. 40

    Brilinta

    US

    ticagrelor · Acute coronary syndrome, heart attack prevention

    Unverified catalogue summary (leaderboard identity and indication) for Brilinta in US; not checked against current local product information.

    $120M

    editorial est. / yr · catalogue record

  41. 41

    Prolia

    US

    denosumab · Osteoporosis

    Unverified catalogue summary (leaderboard identity and indication) for Prolia in US; not checked against current local product information.

    $120M

    editorial est. / yr · catalogue record

  42. 42

    Symbicort

    US

    budesonide/formoterol · Asthma, COPD

    Unverified catalogue summary (leaderboard identity and indication) for Symbicort in US; not checked against current local product information.

    $120M

    editorial est. / yr · catalogue record

  43. 43

    Otezla

    US

    apremilast · Plaque psoriasis, psoriatic arthritis, oral ulcers associated with Behçet's disease

    Unverified catalogue summary (leaderboard identity and indication) for Otezla in US; not checked against current local product information.

    $110M

    editorial est. / yr · catalogue record

  44. 44

    Veozah

    US

    fezolinetant · Menopausal hot flashes

    Unverified catalogue summary (leaderboard identity and indication) for Veozah in US; not checked against current local product information.

    $110M

    editorial est. / yr · catalogue record

  45. 45

    Invokana

    US

    canagliflozin · Type 2 diabetes, diabetic kidney disease

    Unverified catalogue summary (leaderboard identity and indication) for Invokana in US; not checked against current local product information.

    $110M

    editorial est. / yr · catalogue record

  46. 46

    Emgality

    US

    galcanezumab-gnlm · Migraine prevention and episodic cluster headache in adults

    Unverified catalogue summary (leaderboard identity and indication) for Emgality in US; not checked against current local product information.

    $110M

    editorial est. / yr · catalogue record

  47. 47

    Arexvy

    US

    respiratory syncytial virus vaccine, recombinant, adjuvanted · Prevention of RSV lower respiratory tract disease in adults 60+ and adults 18–59 at increased risk

    Unverified catalogue summary (leaderboard identity and indication) for Arexvy in US; not checked against current local product information.

    $110M

    editorial est. / yr · catalogue record

  48. 48

    Restasis

    US

    cyclosporine ophthalmic emulsion · Reduced tear production associated with ocular inflammation in keratoconjunctivitis sicca

    Unverified catalogue summary (leaderboard identity and indication) for Restasis in US; not checked against current local product information.

    $100M

    editorial est. / yr · catalogue record

  49. 49

    Aimovig

    US

    erenumab-aooe · Migraine prevention

    Unverified catalogue summary (leaderboard identity and indication) for Aimovig in US; not checked against current local product information.

    $100M

    editorial est. / yr · catalogue record

  50. 50

    Breo Ellipta

    US

    fluticasone furoate/vilanterol · Asthma, COPD

    Unverified catalogue summary (leaderboard identity and indication) for Breo Ellipta in US; not checked against current local product information.

    $100M

    editorial est. / yr · catalogue record

  51. 51

    Cialis

    US

    tadalafil · Erectile dysfunction, enlarged prostate (BPH)

    Unverified catalogue summary (leaderboard identity and indication) for Cialis in US; not checked against current local product information.

    $100M

    editorial est. / yr · catalogue record

  52. 52

    Humira

    CA

    adalimumab · Rheumatoid arthritis, psoriasis, Crohn's disease

    Unverified catalogue summary (leaderboard identity and indication) for Humira in CA; not checked against current local product information.

    $95M

    editorial est. / yr · catalogue record

  53. 53

    Entyvio

    US

    vedolizumab · Ulcerative colitis, Crohn's disease

    Unverified catalogue summary (leaderboard identity and indication) for Entyvio in US; not checked against current local product information.

    $95M

    editorial est. / yr · catalogue record

  54. 54

    Xolair

    US

    omalizumab · Allergic asthma, chronic spontaneous urticaria and IgE-mediated food allergy

    Unverified catalogue summary (leaderboard identity and indication) for Xolair in US; not checked against current local product information.

    $95M

    editorial est. / yr · catalogue record

  55. 55

    Dovato

    US

    dolutegravir/lamivudine · HIV-1 infection

    Unverified catalogue summary (leaderboard identity and indication) for Dovato in US; not checked against current local product information.

    $95M

    editorial est. / yr · catalogue record

  56. 56

    Leqvio

    US

    inclisiran · High cholesterol

    Unverified catalogue summary (leaderboard identity and indication) for Leqvio in US; not checked against current local product information.

    $90M

    editorial est. / yr · catalogue record

  57. 57

    Vascepa

    US

    icosapent ethyl · High triglycerides, cardiovascular risk reduction

    Unverified catalogue summary (leaderboard identity and indication) for Vascepa in US; not checked against current local product information.

    $90M

    editorial est. / yr · catalogue record

  58. 58

    Eylea

    US

    aflibercept · Wet macular degeneration, diabetic eye disease

    Unverified catalogue summary (leaderboard identity and indication) for Eylea in US; not checked against current local product information.

    $90M

    editorial est. / yr · catalogue record

  59. 59

    Xeljanz

    US

    tofacitinib · Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis

    Unverified catalogue summary (leaderboard identity and indication) for Xeljanz in US; not checked against current local product information.

    $90M

    editorial est. / yr · catalogue record

  60. 60

    Chantix

    US

    varenicline · Smoking cessation

    Unverified catalogue summary (leaderboard identity and indication) for Chantix in US; not checked against current local product information.

    $90M

    editorial est. / yr · catalogue record

  61. 61

    Xtandi

    US

    enzalutamide · Prostate cancer

    Unverified catalogue summary (leaderboard identity and indication) for Xtandi in US; not checked against current local product information.

    $90M

    editorial est. / yr · catalogue record

  62. 62

    Ozempic

    CA

    semaglutide · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Ozempic in CA; not checked against current local product information.

    $85M

    editorial est. / yr · catalogue record

  63. 63

    Verzenio

    US

    abemaciclib · HR+/HER2- breast cancer

    Unverified catalogue summary (leaderboard identity and indication) for Verzenio in US; not checked against current local product information.

    $85M

    editorial est. / yr · catalogue record

  64. 64

    Vabysmo

    US

    faricimab-svoa · Wet macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion

    Unverified catalogue summary (leaderboard identity and indication) for Vabysmo in US; not checked against current local product information.

    $85M

    editorial est. / yr · catalogue record

  65. 65

    Latuda

    US

    lurasidone · Schizophrenia and depressive episodes associated with bipolar I disorder

    Unverified catalogue summary (leaderboard identity and indication) for Latuda in US; not checked against current local product information.

    $85M

    editorial est. / yr · catalogue record

  66. 66

    Ibrance

    US

    palbociclib · HR-positive advanced or metastatic breast cancer, in specified HER2-negative and HER2-positive combination regimens

    Unverified catalogue summary (leaderboard identity and indication) for Ibrance in US; not checked against current local product information.

    $80M

    editorial est. / yr · catalogue record

  67. 67

    Gemtesa

    US

    vibegron · Overactive bladder

    Unverified catalogue summary (leaderboard identity and indication) for Gemtesa in US; not checked against current local product information.

    $80M

    editorial est. / yr · catalogue record

  68. 68

    Fasenra

    US

    benralizumab · Severe eosinophilic asthma

    Unverified catalogue summary (leaderboard identity and indication) for Fasenra in US; not checked against current local product information.

    $80M

    editorial est. / yr · catalogue record

  69. 69

    Mavyret

    US

    glecaprevir/pibrentasvir · Hepatitis C

    Unverified catalogue summary (leaderboard identity and indication) for Mavyret in US; not checked against current local product information.

    $80M

    editorial est. / yr · catalogue record

  70. 70

    Kisqali

    US

    ribociclib · HR-positive, HER2-negative breast cancer

    Unverified catalogue summary (leaderboard identity and indication) for Kisqali in US; not checked against current local product information.

    $80M

    editorial est. / yr · catalogue record

  71. 71

    Eliquis

    CA

    apixaban · Blood clots, atrial fibrillation

    Unverified catalogue summary (leaderboard identity and indication) for Eliquis in CA; not checked against current local product information.

    $75M

    editorial est. / yr · catalogue record

  72. 72

    Cibinqo

    US

    abrocitinib · Refractory moderate-to-severe atopic dermatitis in patients 12 years and older

    Unverified catalogue summary (leaderboard identity and indication) for Cibinqo in US; not checked against current local product information.

    $75M

    editorial est. / yr · catalogue record

  73. 73

    Nucala

    US

    mepolizumab · Severe eosinophilic asthma, COPD, nasal polyps

    Unverified catalogue summary (leaderboard identity and indication) for Nucala in US; not checked against current local product information.

    $75M

    editorial est. / yr · catalogue record

  74. 74

    Quviviq

    US

    daridorexant · Insomnia

    Unverified catalogue summary (leaderboard identity and indication) for Quviviq in US; not checked against current local product information.

    $75M

    editorial est. / yr · catalogue record

  75. 75

    Vuity

    US

    pilocarpine ophthalmic · Age-related blurry near vision (presbyopia)

    Unverified catalogue summary (leaderboard identity and indication) for Vuity in US; not checked against current local product information.

    $70M

    editorial est. / yr · catalogue record

  76. 76

    Evenity

    US

    romosozumab-aqqg · Osteoporosis in postmenopausal women at high fracture risk

    Unverified catalogue summary (leaderboard identity and indication) for Evenity in US; not checked against current local product information.

    $70M

    editorial est. / yr · catalogue record

  77. 77

    Ajovy

    US

    fremanezumab-vfrm · Migraine prevention

    Unverified catalogue summary (leaderboard identity and indication) for Ajovy in US; not checked against current local product information.

    $70M

    editorial est. / yr · catalogue record

  78. 78

    Tezspire

    US

    tezepelumab-ekko · Severe asthma

    Unverified catalogue summary (leaderboard identity and indication) for Tezspire in US; not checked against current local product information.

    $70M

    editorial est. / yr · catalogue record

  79. 79

    Vyvanse

    US

    lisdexamfetamine · ADHD, binge eating disorder

    Unverified catalogue summary (leaderboard identity and indication) for Vyvanse in US; not checked against current local product information.

    $70M

    editorial est. / yr · catalogue record

  80. 80

    Dupixent

    CA

    dupilumab · Moderate-to-severe atopic dermatitis, severe type 2/eosinophilic or oral corticosteroid-dependent asthma, severe chronic rhinosinusitis with nasal polyps

    Unverified catalogue summary (leaderboard identity and indication) for Dupixent in CA; not checked against current local product information.

    $65M

    editorial est. / yr · catalogue record

  81. 81

    Litfulo

    US

    ritlecitinib · Severe alopecia areata

    Unverified catalogue summary (leaderboard identity and indication) for Litfulo in US; not checked against current local product information.

    $65M

    editorial est. / yr · catalogue record

  82. 82

    Icotyde

    US

    icotrokinra · Plaque psoriasis

    Unverified catalogue summary (leaderboard identity and indication) for Icotyde in US; not checked against current local product information.

    $65M

    editorial est. / yr · catalogue record

  83. 83

    Lipitor

    US

    atorvastatin · High cholesterol, cardiovascular prevention

    Unverified catalogue summary (leaderboard identity and indication) for Lipitor in US; not checked against current local product information.

    $60M

    editorial est. / yr · catalogue record

  84. 84

    Kerendia

    US

    finerenone · CKD associated with type 2 or type 1 diabetes; heart failure with LVEF ≥40%

    Unverified catalogue summary (leaderboard identity and indication) for Kerendia in US; not checked against current local product information.

    $60M

    editorial est. / yr · catalogue record

  85. 85

    Olumiant

    US

    baricitinib · Rheumatoid arthritis, severe alopecia areata

    Unverified catalogue summary (leaderboard identity and indication) for Olumiant in US; not checked against current local product information.

    $60M

    editorial est. / yr · catalogue record

  86. 86

    Paxlovid

    US

    nirmatrelvir/ritonavir · Mild-to-moderate COVID-19 in adults at high risk for progression to severe disease

    Unverified catalogue summary (leaderboard identity and indication) for Paxlovid in US; not checked against current local product information.

    $60M

    editorial est. / yr · catalogue record

  87. 87

    Orilissa

    US

    elagolix · Endometriosis pain

    Unverified catalogue summary (leaderboard identity and indication) for Orilissa in US; not checked against current local product information.

    $60M

    editorial est. / yr · catalogue record

  88. 88

    Jardiance

    CA

    empagliflozin · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Jardiance in CA; not checked against current local product information.

    $55M

    editorial est. / yr · catalogue record

  89. 89

    Bimzelx

    US

    bimekizumab-bkzx · Plaque psoriasis, psoriatic arthritis

    Unverified catalogue summary (leaderboard identity and indication) for Bimzelx in US; not checked against current local product information.

    $55M

    editorial est. / yr · catalogue record

  90. 90

    Auvelity

    US

    dextromethorphan/bupropion · Major depressive disorder in adults; agitation associated with dementia due to Alzheimer's disease

    Unverified catalogue summary (leaderboard identity and indication) for Auvelity in US; not checked against current local product information.

    $50M

    editorial est. / yr · catalogue record

  91. 91

    Skyrizi

    CA

    risankizumab · Plaque psoriasis, psoriatic arthritis, Crohn's disease

    Unverified catalogue summary (leaderboard identity and indication) for Skyrizi in CA; not checked against current local product information.

    $48M

    editorial est. / yr · catalogue record

  92. 92

    Crestor

    US

    rosuvastatin · High cholesterol, cardiovascular prevention

    Unverified catalogue summary (leaderboard identity and indication) for Crestor in US; not checked against current local product information.

    $45M

    editorial est. / yr · catalogue record

  93. 93

    Keytruda

    CA

    pembrolizumab · Multiple cancers

    Unverified catalogue summary (leaderboard identity and indication) for Keytruda in CA; not checked against current local product information.

    $42M

    editorial est. / yr · catalogue record

  94. 94

    Mounjaro

    CA

    tirzepatide · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Mounjaro in CA; not checked against current local product information.

    $40M

    editorial est. / yr · catalogue record

  95. 95

    Rinvoq

    CA

    upadacitinib · Rheumatoid arthritis, psoriatic arthritis, eczema

    Unverified catalogue summary (leaderboard identity and indication) for Rinvoq in CA; not checked against current local product information.

    $38M

    editorial est. / yr · catalogue record

  96. 96

    Repatha

    CA

    evolocumab · High cholesterol, cardiovascular disease

    Unverified catalogue summary (leaderboard identity and indication) for Repatha in CA; not checked against current local product information.

    $32M

    editorial est. / yr · catalogue record

  97. 97

    Victoza

    CA

    liraglutide · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Victoza in CA; not checked against current local product information.

    $28M

    editorial est. / yr · catalogue record

  98. 98

    Xarelto

    CA

    rivaroxaban · Blood clots, atrial fibrillation

    Unverified catalogue summary (leaderboard identity and indication) for Xarelto in CA; not checked against current local product information.

    $28M

    editorial est. / yr · catalogue record

  99. 99

    Trulicity

    CA

    dulaglutide · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Trulicity in CA; not checked against current local product information.

    $26M

    editorial est. / yr · catalogue record

  100. 100

    Tylenol

    CA

    acetaminophen · Pain relief, fever

    Unverified catalogue summary (leaderboard identity and indication) for Tylenol in CA; not checked against current local product information.

    $14M

    editorial est. / yr · catalogue record

  101. 101

    Advair

    CA

    fluticasone propionate/salmeterol · Maintenance treatment of asthma; COPD maintenance with Advair Diskus 250 or 500

    Unverified catalogue summary (leaderboard identity and indication) for Advair in CA; not checked against current local product information.

    $12M

    editorial est. / yr · catalogue record

  102. 102

    Voltaren

    NZ

    diclofenac · Arthritis, muscle pain, joint pain

    Unverified catalogue summary (leaderboard identity and indication) for Voltaren in NZ; not checked against current local product information.

    $12M

    editorial est. / yr · catalogue record

  103. 103

    Symbicort

    CA

    budesonide/formoterol · Asthma, COPD

    Unverified catalogue summary (leaderboard identity and indication) for Symbicort in CA; not checked against current local product information.

    $11M

    editorial est. / yr · catalogue record

  104. 104

    Nurofen

    NZ

    ibuprofen · Pain relief, inflammation, fever

    Unverified catalogue summary (leaderboard identity and indication) for Nurofen in NZ; not checked against current local product information.

    $10M

    editorial est. / yr · catalogue record

  105. 105

    Nexium

    CA

    esomeprazole · Acid reflux, GERD, ulcers

    Unverified catalogue summary (leaderboard identity and indication) for Nexium in CA; not checked against current local product information.

    $9M

    editorial est. / yr · catalogue record

  106. 106

    Lipitor

    CA

    atorvastatin · High cholesterol, cardiovascular prevention

    Unverified catalogue summary (leaderboard identity and indication) for Lipitor in CA; not checked against current local product information.

    $8M

    editorial est. / yr · catalogue record

  107. 107

    Nasonex

    NZ

    mometasone · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Nasonex in NZ; not checked against current local product information.

    $8M

    editorial est. / yr · catalogue record

  108. 108

    Nicorette

    NZ

    nicotine · Smoking cessation

    Unverified catalogue summary (leaderboard identity and indication) for Nicorette in NZ; not checked against current local product information.

    $8M

    editorial est. / yr · catalogue record

  109. 109

    Crestor

    CA

    rosuvastatin · High cholesterol, cardiovascular prevention

    Unverified catalogue summary (leaderboard identity and indication) for Crestor in CA; not checked against current local product information.

    $7M

    editorial est. / yr · catalogue record

  110. 110

    Ventolin

    CA

    salbutamol · Asthma, bronchospasm

    Unverified catalogue summary (leaderboard identity and indication) for Ventolin in CA; not checked against current local product information.

    $6M

    editorial est. / yr · catalogue record

  111. 111

    Nexium

    NZ

    esomeprazole · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Nexium in NZ; not checked against current local product information.

    $6M

    editorial est. / yr · catalogue record

  112. 112

    Claratyne

    NZ

    loratadine · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Claratyne in NZ; not checked against current local product information.

    $6M

    editorial est. / yr · catalogue record

  113. 113

    Synthroid

    CA

    levothyroxine sodium · Hypothyroidism

    Unverified catalogue summary (leaderboard identity and indication) for Synthroid in CA; not checked against current local product information.

    $5M

    editorial est. / yr · catalogue record

  114. 114

    Panadol

    NZ

    paracetamol · Pain relief, fever

    Unverified catalogue summary (leaderboard identity and indication) for Panadol in NZ; not checked against current local product information.

    $5M

    editorial est. / yr · catalogue record

  115. 115

    Fosamax

    NZ

    alendronate · Osteoporosis

    Unverified catalogue summary (leaderboard identity and indication) for Fosamax in NZ; not checked against current local product information.

    $5M

    editorial est. / yr · catalogue record

  116. 116

    Cipralex

    CA

    escitalopram · Depression, anxiety

    Unverified catalogue summary (leaderboard identity and indication) for Cipralex in CA; not checked against current local product information.

    $4M

    editorial est. / yr · catalogue record

  117. 117

    Telfast

    NZ

    fexofenadine · Hay fever, allergic rhinitis, hives

    Unverified catalogue summary (leaderboard identity and indication) for Telfast in NZ; not checked against current local product information.

    $4M

    editorial est. / yr · catalogue record

  118. 118

    Champix

    NZ

    varenicline · Smoking cessation

    Unverified catalogue summary (leaderboard identity and indication) for Champix in NZ; not checked against current local product information.

    $4M

    editorial est. / yr · catalogue record

  119. 119

    Zyrtec

    NZ

    cetirizine · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Zyrtec in NZ; not checked against current local product information.

    $4M

    editorial est. / yr · catalogue record

  120. 120

    Lipitor

    NZ

    atorvastatin · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Lipitor in NZ; not checked against current local product information.

    $4M

    editorial est. / yr · catalogue record

  121. 121

    Concerta

    CA

    methylphenidate hydrochloride · ADHD

    Unverified catalogue summary (leaderboard identity and indication) for Concerta in CA; not checked against current local product information.

    $3M

    editorial est. / yr · catalogue record

  122. 122

    Losec

    NZ

    omeprazole · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Losec in NZ; not checked against current local product information.

    $3M

    editorial est. / yr · catalogue record

  123. 123

    Ozempic

    NZ

    semaglutide · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Ozempic in NZ; not checked against current local product information.

    $3M

    editorial est. / yr · catalogue record

  124. 124

    Otrivin

    NZ

    xylometazoline · Nasal congestion, cold and sinus relief

    Unverified catalogue summary (leaderboard identity and indication) for Otrivin in NZ; not checked against current local product information.

    $3M

    editorial est. / yr · catalogue record

  125. 125

    Ventolin

    NZ

    salbutamol · Asthma, bronchospasm

    Unverified catalogue summary (leaderboard identity and indication) for Ventolin in NZ; not checked against current local product information.

    $3M

    editorial est. / yr · catalogue record

  126. 126

    Symbicort

    NZ

    budesonide/formoterol · Asthma, COPD

    Unverified catalogue summary (leaderboard identity and indication) for Symbicort in NZ; not checked against current local product information.

    $3M

    editorial est. / yr · catalogue record

  127. 127

    Altace

    CA

    ramipril · High blood pressure, heart protection

    Unverified catalogue summary (leaderboard identity and indication) for Altace in CA; not checked against current local product information.

    $2M

    editorial est. / yr · catalogue record

  128. 128

    Glucophage

    CA

    metformin hydrochloride · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Glucophage in CA; not checked against current local product information.

    $2M

    editorial est. / yr · catalogue record

  129. 129

    Pantoloc

    CA

    pantoprazole · Acid reflux, GERD, ulcers

    Unverified catalogue summary (leaderboard identity and indication) for Pantoloc in CA; not checked against current local product information.

    $2M

    editorial est. / yr · catalogue record

  130. 130

    Seretide

    NZ

    fluticasone propionate/salmeterol · Asthma, COPD

    Unverified catalogue summary (leaderboard identity and indication) for Seretide in NZ; not checked against current local product information.

    $2M

    editorial est. / yr · catalogue record

  131. 131

    Jardiance

    NZ

    empagliflozin · Type 2 diabetes, heart failure

    Unverified catalogue summary (leaderboard identity and indication) for Jardiance in NZ; not checked against current local product information.

    $2M

    editorial est. / yr · catalogue record

  132. 132

    Metformin

    US

    metformin · Type 2 diabetes

    Unverified catalogue summary (leaderboard identity and indication) for Metformin in US; not checked against current local product information.

    $2M

    editorial est. / yr · catalogue record

  133. 133

    Cymbalta

    NZ

    duloxetine · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Cymbalta in NZ; not checked against current local product information.

    $2M

    editorial est. / yr · catalogue record

  134. 134

    Glucophage

    NZ

    metformin · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Glucophage in NZ; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  135. 135

    Augmentin

    NZ

    amoxicillin/clavulanate · Bacterial infections

    Unverified catalogue summary (leaderboard identity and indication) for Augmentin in NZ; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  136. 136

    Loxalate

    NZ

    escitalopram · Depression, anxiety

    Unverified catalogue summary (leaderboard identity and indication) for Loxalate in NZ; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  137. 137

    Mobic

    NZ

    meloxicam · Arthritis, joint inflammation

    Unverified catalogue summary (leaderboard identity and indication) for Mobic in NZ; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  138. 138

    Somac

    NZ

    pantoprazole · See official local label

    Unverified catalogue summary (leaderboard identity and indication) for Somac in NZ; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  139. 139

    Lisinopril

    US

    lisinopril · High blood pressure, heart failure

    Unverified catalogue summary (leaderboard identity and indication) for Lisinopril in US; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  140. 140

    Amoxicillin

    US

    amoxicillin · Bacterial infections

    Unverified catalogue summary (leaderboard identity and indication) for Amoxicillin in US; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  141. 141

    Gabapentin

    US

    gabapentin · Adult postherpetic neuralgia; partial-onset seizures (add-on, age 3+)

    Unverified catalogue summary (leaderboard identity and indication) for Gabapentin in US; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  142. 142

    Adderall

    US

    amphetamine/dextroamphetamine · ADHD, narcolepsy

    Unverified catalogue summary (leaderboard identity and indication) for Adderall in US; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  143. 143

    Synthroid

    US

    levothyroxine · Hypothyroidism

    Unverified catalogue summary (leaderboard identity and indication) for Synthroid in US; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  144. 144

    Prednisone

    US

    prednisone · Inflammation, autoimmune flares, allergic reactions

    Unverified catalogue summary (leaderboard identity and indication) for Prednisone in US; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

  145. 145

    Zoloft

    US

    sertraline · Major depression, OCD, panic disorder, PTSD, social anxiety disorder, PMDD

    Unverified catalogue summary (leaderboard identity and indication) for Zoloft in US; not checked against current local product information.

    $1M

    editorial est. / yr · catalogue record

TV drug ad spend: frequently asked questions

Which prescription drug spends the most on TV advertising?

Humira has the largest estimated TV ad budget at about $500M a year in TVPills' internal editorial estimates, ranking first among the drugs we track. This is not verified spending.

How much do prescription drugs spend on TV ads in total?

The 145 TV-advertised drugs in the selected country filter have a combined TVPills internal editorial estimate of annual TV ad budgets of about $13.2B. This is not measured spending.

Why do drug companies advertise so much on TV?

Prescription drugs are among the most heavily advertised products on American television because direct-to-consumer ads encourage patients to ask their doctors about brand-name medicines — which can drive significant sales for high-priced drugs.

Which countries allow prescription drug ads on TV?

Only the United States and New Zealand allow full direct-to-consumer prescription drug advertising, so nearly all TV drug ad spending happens in those two countries.

Sources & methodology

Source dataset: TVPills maintained drug catalogue (TVPills Editorial Team). The catalogue snapshot used for these figures was retrieved June 30, 2026.

Calculation: Each drug record's tvAdBudgetMillions value is treated as an estimated annual budget in millions of US dollars. Rankings sort records descending by that value; totals and group totals sum each positive record once, without weighting or extrapolating from commercial counts. Each individual amount in the rankings links to the corresponding catalogue record; grouped totals use the same record-level values.

Limitations: These values are editorial estimates, not company-reported or independently audited media-buying figures. The catalogue does not currently attach a public third-party publication to each estimate, so the figures should not be used as financial, investment, or market-size data.

Source status: Internal editorial estimate. No company filing or independent media-buying dataset is being presented as the source for these values.

Embed this leaderboard

Run a health, news, or finance site? Drop this leaderboard into any page — it stays up to date automatically. Please keep the credit link.